Janssen-Cilag International NV Release: INVEGA® Receives European Commission Approval To Extend Its Adult Indication For Treatment Of Schizophrenia To Include Adolescents Aged 15 Years And Older
6/4/2014 8:43:13 AM
BEERSE, Belgium, 4 June 2014: Janssen-Cilag International NV announced today that the European Commission has approved an extension of the oral atypical antipsychotic INVEGA® (paliperidone ER) schizophrenia indication, to include adolescents aged 15 years and older.1 The decision from the European Commission follows a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency in April 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by